G

GemVax & KAEL Co Ltd
KOSDAQ:082270

Watchlist Manager
GemVax & KAEL Co Ltd
KOSDAQ:082270
Watchlist
Price: 28 550 KRW 4.58% Market Closed
Market Cap: 1.2T KRW

Intrinsic Value

The intrinsic value of one GemVax & KAEL Co Ltd stock under the Base Case scenario is 5 052.23 KRW. Compared to the current market price of 28 550 KRW, GemVax & KAEL Co Ltd is Overvalued by 82%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
5 052.23 KRW
Overvaluation 82%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation History
GemVax & KAEL Co Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about GemVax & KAEL Co Ltd?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is GemVax & KAEL Co Ltd valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for GemVax & KAEL Co Ltd.

Explain Valuation
Compare GemVax & KAEL Co Ltd to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about GemVax & KAEL Co Ltd?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
GemVax & KAEL Co Ltd

Current Assets 40B
Cash & Short-Term Investments 17.9B
Receivables 11.3B
Other Current Assets 10.8B
Non-Current Assets 122.3B
Long-Term Investments 48.1B
PP&E 33.4B
Intangibles 2.7B
Other Non-Current Assets 38.1B
Current Liabilities 66.2B
Accounts Payable 3.4B
Accrued Liabilities 4.5B
Short-Term Debt 34.2B
Other Current Liabilities 24.1B
Non-Current Liabilities 55.2B
Long-Term Debt 24.3B
Other Non-Current Liabilities 30.9B
Efficiency

Free Cash Flow Analysis
GemVax & KAEL Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
GemVax & KAEL Co Ltd

Revenue
68.4B KRW
Cost of Revenue
-45B KRW
Gross Profit
23.4B KRW
Operating Expenses
-44.8B KRW
Operating Income
-21.5B KRW
Other Expenses
-43.9B KRW
Net Income
-65.4B KRW
Fundamental Scores

Profitability Score
Profitability Due Diligence

GemVax & KAEL Co Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin
Sustainable 3Y Average Gross Margin
Gross Margin is Increasing
Declining Net Margin
17/100
Profitability
Score

GemVax & KAEL Co Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

GemVax & KAEL Co Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Average D/E
Positive Net Debt
42/100
Solvency
Score

GemVax & KAEL Co Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
GemVax & KAEL Co Ltd

There are no price targets for GemVax & KAEL Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GemVax & KAEL Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one GemVax & KAEL Co Ltd stock?

The intrinsic value of one GemVax & KAEL Co Ltd stock under the Base Case scenario is 5 052.23 KRW.

Is GemVax & KAEL Co Ltd stock undervalued or overvalued?

Compared to the current market price of 28 550 KRW, GemVax & KAEL Co Ltd is Overvalued by 82%.

Back to Top